EGFR and non-small cell lung carcinoma: Patients who are classified as VeriStrat-poor may benefit from the addition of ficlatuzumab.57 However, a recent phase II study (NCT02318368) comparing first-line treatment with ficlatuzumab plus erlotinib versus erlotinib monotherapy in VeriStrat-poor patients with EGFR-mutated NSCLC was discontinued because of a high discontinuation rate in the combination treatment arm.